Altimmune: Pemvidutide Phase 2b win and $183M cash bolster runway despite losses, dilution

Altimmune, Inc. (ALT) - quick read: late clinical‑stage biotech; pemvidutide Phase 2b (IMPACT) reported strong topline efficacy; company materially strengthened cash position in H1 2025 via equity raises and a term loan, but still reports no product revenue and substantial ongoing losses.

All dollar amounts below are reported in thousands (USD) except per‑share amounts and share counts; figures are taken from Altimmune's 10‑Q for the quarter ended June 30, 2025.

Key financials & statistics (as reported)
* Cash and cash equivalents: $183,105 (June 30, 2025)
* Total cash, cash equivalents and restricted cash: $183,147 (June 30, 2025)
* Short‑term investments: $- (vs $94,965 at 12/31/2024)
* Total assets: $190,350 (June 30, 2025) vs $139,306 (12/31/2024)
* Total liabilities: $28,983 (June 30, 2025) vs $15,798 (12/31/2024)
* Term loan (net of discount/fees): $14,332 (noncurrent) - first tranche funded $15,000 on May 13, 2025; effective interest ~14.4%
* Stockholders' equity: $161,367 (June 30, 2025) vs $123,508 (12/31/2024)
* Shares issued & outstanding: 85,076,300 (June 30, 2025) vs 72,352,701 (12/31/2024)
* Accumulated deficit: $(603,111) (June 30, 2025)

Income statement - selected items (three months ended June 30, 2025 vs 2024)
* Revenues: $5 (Q2 2025) vs $5 (Q2 2024)
* Research & development expense: $17,236 vs $21,155 (down 19%)
* General & administrative expense: $5,691 vs $5,595 (up 2%)
* Total operating expenses: $22,927 vs $26,750 (down 14%)
* Loss from operations: $(22,922) vs $(26,745)
* Interest income: $1,132 vs $2,182 (decline due to lower short‑term investments)
* Interest expense: $(264) vs $(1) (increase from term loan)
* Net loss: $(22,146) vs $(24,640) (improved ~10%)
* Net loss per share, basic & diluted: $(0.27) vs $(0.35)
* Weighted‑average common shares outstanding: 81,477,548 vs 70,924,371

Six months (YTD) highlights
* Revenues (YTD): $10 (unchanged year‑over‑year)
* R&D YTD: $33,063 vs $42,642 (down 22%) - MASH spending reduced as enrollment progressed; new AUD & ALD trial costs beginning
* Total operating expense YTD: $44,747 vs $53,549 (down 16%)
* Net loss YTD: $(41,721) vs $(49,034) (improved ~15%)
* Net loss per share YTD: $(0.53) vs $(0.69)

Cash flow & financing
* Net cash used in operating activities (six months): $(36,190) vs $(34,465)
* Net cash provided by investing activities: $96,006 (sale/maturities of investments) vs $(43,217)
* Net cash provided by financing activities: $86,363 (includes ~$72,571 net ATM proceeds and $15,000 term loan) vs $(307)
* Net increase in cash and restricted cash: $146,179 (six months)

Positive aspects (income statement & corporate position)
* Operating costs down: R&D and total operating expenses declined vs prior year periods (R&D down 19% Q/Q; 22% YTD) reflecting lower MASH trial spend and manufacturing savings.
* Reduced net loss: Net loss improved ~10% Q/Q and ~15% YTD vs 2024 - trend in the right direction.
* Strong cash position: Cash + equivalents $183.1M as of 6/30/2025 (major buffer for operations and clinical programs).
* Clinical win: IMPACT Phase 2b topline reported strong MASH efficacy (company disclosed statistically significant MASH resolution vs placebo) - materially de‑risking the lead program and supporting new indication launches (AUD, ALD).

Negative aspects / risks (income statement & other)
* No product revenue: Revenue remains immaterial ($10 YTD); the company is pre‑commercial and dependent on financing.
* Substantial ongoing losses: Net loss continues - accumulated deficit $(603,111). Operating cash burn still ~ $36M over six months.
* Dilution: Shares outstanding rose to 85.08M from 72.35M (equity raises and ATMs) - financing reduced cash risk but diluted holders.
* Debt cost & covenants: Term loan carries high effective interest (~14.4%) plus end‑of‑term charge; loan secured by substantially all assets and contains customary covenants and prepayment penalties.
* Falling interest income: Interest income dropped as short‑term investments were monetized, increasing reliance on operating cash and financing.
* Share‑based compensation / overhang: Options outstanding ~8.10M; unvested RSUs ~1.04M - future dilution and non‑cash expense of ~$21M (unrecognized for options) and ~$6.8M (RSUs) to be recognized over the next ~3 years.
* Legal risk: Securities class action (filed Aug 5, 2025) and prior derivative litigation - litigation may be costly and distracting.

What's happening inside the company (operational/strategic points)
* Clinical: Pemvidutide IMPACT Phase 2b (MASH) topline positive (statistically significant MASH resolution vs placebo; weight loss and non‑invasive fibrosis markers improved).
* Pipeline expansion: Company launched/started Phase 2 trials RECLAIM (AUD) and RESTORE (ALD); both use 2.4 mg pemvidutide dosing and increase program breadth and potential market size.
* Financing strategy: Raised material equity via at‑the‑market offerings (~$72.6M net in H1 2025) and drew $15M first tranche of a $100M term loan; remaining ATM capacity and subsequent raises provide runway. Company stated cash is sufficient for at least 12 months from 6/30/2025.
* Cost posture: R&D spend shifted down as MASH enrollment wound down; new trial starts are increasing targeted spend in AUD/ALD.
* Governance & controls: Management reports disclosure controls effective as of 6/30/2025.

Bottom line (straightforward)
Altimmune (NASDAQ: ALT) has a clinically meaningful positive data point for its lead asset (pemvidutide) and a much stronger cash position after equity raises and a term loan. That reduces near‑term execution risk and funds new trials. However, the company remains pre‑revenue, continues to incur large R&D losses, has diluted shareholders via recent offerings, carries relatively expensive secured debt, and faces litigation risk. Investors should weigh the clinical upside and extended runway against continued burn, dilution, and debt cost.

If you want, I can convert these facts into a short investor note with a one‑sentence buy/hold/sell view and a simple valuation / runway sensitivity table.